EBS vs. RGLS, BOLT, FBIO, RIGL, MACK, VSTM, VNDA, XOMA, LXRX, and DMAC
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Regulus Therapeutics (RGLS), Bolt Biotherapeutics (BOLT), Fortress Biotech (FBIO), Rigel Pharmaceuticals (RIGL), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry.
Emergent BioSolutions (NYSE:EBS) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Regulus Therapeutics has a net margin of 0.00% compared to Emergent BioSolutions' net margin of -47.68%. Emergent BioSolutions' return on equity of -18.53% beat Regulus Therapeutics' return on equity.
Emergent BioSolutions currently has a consensus price target of $5.00, suggesting a potential upside of 13.38%. Regulus Therapeutics has a consensus price target of $7.25, suggesting a potential upside of 225.11%. Given Regulus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Regulus Therapeutics is more favorable than Emergent BioSolutions.
Emergent BioSolutions has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Regulus Therapeutics received 69 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.45% of users gave Emergent BioSolutions an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
In the previous week, Emergent BioSolutions had 15 more articles in the media than Regulus Therapeutics. MarketBeat recorded 22 mentions for Emergent BioSolutions and 7 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 0.37 beat Emergent BioSolutions' score of 0.32 indicating that Regulus Therapeutics is being referred to more favorably in the news media.
Regulus Therapeutics has lower revenue, but higher earnings than Emergent BioSolutions. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Summary
Regulus Therapeutics beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
